{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:08:18Z","timestamp":1789632498588,"version":"build-2803163510"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Immune checkpoint inhibitors have proven to be effective for various advanced neoplasia. Immune-related adverse events (irAEs) as a result of increased T cell activation are unique and potentially life-threating toxicities associated with the use of immune checkpoint inhibitors. Multiple endocrine irAEs, including primary hyperthyroidism and hypothyroidism, thyroiditis, primary adrenal insufficiency, type 1 diabetes mellitus, and hypophysitis, have been reported with the use of various immune checkpoint inhibitors. In some cases, these irAEs can lead to discontinuation of treatment. Here we propose for the general oncologist algorithms for managing endocrine irAEs to aid in the clinical care of patients receiving immunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>There is a relative high risk of endocrine immune-related adverse events (irAEs) during therapy with checkpoint inhibitors, particularly when combination therapy is implemented. Patients treated with anti-CTLA-4 antibodies have an increased risk of hypophysitis, whereas patients treated with anti-PD-1\/PD-L1 antibodies have a higher risk of primary thyroid dysfunction. Rarely, patients develop T1DM and central diabetes insipidus, and hypoparathyroidism is a rare occurrence. A growing clinical understanding of endocrine irAEs has led to effective treatment strategies with hormone replacement.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0470","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T19:35:29Z","timestamp":1570736129000},"page":"290-300","source":"Crossref","is-referenced-by-count":66,"title":["Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management"],"prefix":"10.1093","volume":"25","author":[{"given":"Jaydira","family":"Del Rivero","sequence":"first","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Cordes","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Klubo-Gwiezdzinska","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette K.","family":"Nieman","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"2021122510223225000_R1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/JTO.0000000000000551","article-title":"Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy","volume":"10","author":"Carbone","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2021122510223225000_R8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Cimino-Mathews","year":"2016","journal-title":"Hum Pathol"},{"key":"2021122510223225000_R9","first-page":"1","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Diaz","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R10","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122510223225000_R11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1756287215607418","article-title":"Muscle-invasive urothelial bladder cancer: An update on systemic therapy","volume":"7","author":"Knollman","year":"2015","journal-title":"Ther Adv Urol"},{"key":"2021122510223225000_R12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R14","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","article-title":"Antagonists of PD-1 and PD-L1 in cancer treatment","volume":"42","author":"Lipson","year":"2015","journal-title":"Semin Oncol"},{"key":"2021122510223225000_R16","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122510223225000_R18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510223225000_R19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122510223225000_R20","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2217\/fon-2017-0696","article-title":"Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer","volume":"14","author":"Mehrvarz Sarshekeh","year":"2018","journal-title":"Future Oncol"},{"key":"2021122510223225000_R21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2021122510223225000_R22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122510223225000_R23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jgh.12888","article-title":"Ipilimumab-induced toxicities and the gastroenterologist","volume":"30","author":"Cheng","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"2021122510223225000_R24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.mayocp.2013.01.015","article-title":"Association between ipilimumab and celiac disease","volume":"88","author":"Gentile","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"2021122510223225000_R25","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2217\/fon.15.118","article-title":"Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: A meta-analysis","volume":"11","author":"Abdel-Rahman","year":"2015","journal-title":"Future Oncol"},{"key":"2021122510223225000_R26","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"2021122510223225000_R27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000070","article-title":"Peripheral neuropathy associated with ipilimumab: A report of 2 cases","volume":"38","author":"Thaipisuttikul","year":"2015","journal-title":"J Immunother"},{"key":"2021122510223225000_R28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","article-title":"Neurological immune-related adverse events of ipilimumab","volume":"13","author":"Bot","year":"2013","journal-title":"Pract Neurol"},{"key":"2021122510223225000_R29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","article-title":"A severe case of ipilimumab-induced guillain-barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: A differential diagnosis for ipilimumab-induced colitis","volume":"36","author":"Gaudy-Marqueste","year":"2013","journal-title":"J Immunother"},{"key":"2021122510223225000_R30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.12-1467","article-title":"Organizing pneumonia as a side effect of ipilimumab treatment of melanoma","volume":"143","author":"Barjaktarevic","year":"2013","journal-title":"Chest"},{"key":"2021122510223225000_R31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"2021122510223225000_R32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R33","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","article-title":"Ipilimumab granulomatous interstitial nephritis","volume":"22","author":"Thajudeen","year":"2015","journal-title":"Am J Ther"},{"key":"2021122510223225000_R34","first-page":"4607","article-title":"Ipilimumab-induced immune-related renal failure\u2013a case report","volume":"32","author":"Forde","year":"2012","journal-title":"Anticancer Res"},{"key":"2021122510223225000_R35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/CJI.0000000000000041","article-title":"Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma","volume":"37","author":"Rusquec","year":"2014","journal-title":"J Immunother"},{"key":"2021122510223225000_R36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1752-1947-8-240","article-title":"Serious haematological toxicity during and after ipilimumab treatment: A case series","volume":"8","author":"Simeone","year":"2014","journal-title":"J Med Case Rep"},{"key":"2021122510223225000_R37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000377650","article-title":"Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - Case report","volume":"38","author":"Wozniak","year":"2015","journal-title":"Oncol Res Treat"},{"key":"2021122510223225000_R38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","article-title":"Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody)","volume":"32","author":"Akhtari","year":"2009","journal-title":"J Immunother"},{"key":"2021122510223225000_R39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1078155211411001","article-title":"Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma","volume":"18","author":"Ahmad","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"2021122510223225000_R40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/jjco\/hyu222","article-title":"Treatment possibilities of ipilimumab-induced thrombocytopenia\u2013case study and literature review","volume":"45","author":"Kopeck\u00fd","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2021122510223225000_R41","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122510223225000_R42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","article-title":"Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis","volume":"27","author":"Robinson","year":"2004","journal-title":"J Immunother"},{"key":"2021122510223225000_R43","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jcjo.2014.10.010","article-title":"New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient","volume":"50","author":"Miserocchi","year":"2015","journal-title":"Can J Ophthalmo"},{"key":"2021122510223225000_R44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annder.2013.02.029","article-title":"Orbital myositis associated with ipilimumab","volume":"140","author":"Lecouflet","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"2021122510223225000_R45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40425-014-0041-1","article-title":"Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma","volume":"2","author":"Manusow","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2021122510223225000_R46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122510223225000_R47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021122510223225000_R48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","article-title":"Ipilimumab-induced acute severe colitis treated by infliximab","volume":"23","author":"Pag\u00e8s","year":"2013","journal-title":"Melanoma Res"},{"key":"2021122510223225000_R49","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122510223225000_R50","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-13-0434","article-title":"Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: Clinical evidence and pathogenic hypotheses","volume":"169","author":"Torino","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2021122510223225000_R51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2021122510223225000_R52","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122510223225000_R53","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122510223225000_R54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ando.2018.07.007","article-title":"Expert opinion on thyroid complications in immunotherapy","volume":"79","author":"Illouz","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"2021122510223225000_R56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - Immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"2021122510223225000_R57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2021122510223225000_R58","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"2021122510223225000_R59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"2021122510223225000_R60","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa","year":"2018","journal-title":"Cancer"},{"key":"2021122510223225000_R61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"2021122510223225000_R62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122510223225000_R63","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"2021122510223225000_R64","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122510223225000_R65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2021122510223225000_R66","first-page":"3225","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade","volume":"186","author":"Caturegli","year":"2016","journal-title":"Insights into pathogenesis from an autopsy series. Am J Pathol"},{"key":"2021122510223225000_R67","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"2021122510223225000_R68","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122510223225000_R69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: An endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122510223225000_R70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"key":"2021122510223225000_R71","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: An Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122510223225000_R72","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1158\/2326-6066.CIR-14-0217","article-title":"Survivorship in immune therapy: Assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2021122510223225000_R73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PPO.0000000000000186","article-title":"Managing adverse events with immune checkpoint agents","volume":"22","author":"Dadu","year":"2016","journal-title":"Cancer J"},{"key":"2021122510223225000_R74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2021122510223225000_R75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122510223225000_R76","first-page":"41","article-title":"CTLA-4 gene polymorphism associated with Graves\u2019 disease in a Caucasian population","volume":"80","author":"Yanagawa","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122510223225000_R77","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"2021122510223225000_R78","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122510223225000_R79","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122510223225000_R80","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2021122510223225000_R81","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122510223225000_R82","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: A case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"key":"2021122510223225000_R83","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122510223225000_R84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169283","article-title":"The prevalence, incidence and natural course of positive antithyroperoxidase antibodies in a population-based study: Tehran thyroid study","volume":"12","author":"Amouzegar","year":"2017","journal-title":"PLoS One"},{"key":"2021122510223225000_R85","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2021122510223225000_R86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ecl.2006.09.008","article-title":"Thyrotoxicosis and thyroid storm","volume":"35","author":"Nayak","year":"2006","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2021122510223225000_R87","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"2021122510223225000_R88","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0889-8529(18)30165-8","article-title":"Life-threatening thyrotoxicosis. Thyroid storm","volume":"22","author":"Burch","year":"1993","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2021122510223225000_R89","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"Mini-review. J Clin Endocrinol Metab"},{"key":"2021122510223225000_R90","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(16)30582-7","article-title":"Genetic risk factors for type 1 diabetes","volume":"387","author":"Pociot","year":"2016","journal-title":"Lancet"},{"key":"2021122510223225000_R91","doi-asserted-by":"crossref","first-page":"9570424","DOI":"10.1155\/2016\/9570424","article-title":"Genetic risk score modelling for disease progression in new-onset type 1 diabetes patients: Increased genetic load of islet-expressed and cytokine-regulated candidate genes predicts poorer glycemic control","volume":"2016","author":"Brorsson","year":"2016","journal-title":"J Diabetes Res"},{"key":"2021122510223225000_R92","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"2021122510223225000_R93","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/M15-3016","article-title":"Diagnosis and management of diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes","volume":"164","author":"Chamberlain","year":"2016","journal-title":"Ann Intern Med"},{"key":"2021122510223225000_R94","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122510223225000_R95","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: Review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"The Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0470","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/290\/41919581\/oncolo_25_4_290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/290\/41919581\/oncolo_25_4_290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:23:28Z","timestamp":1640427808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/4\/290\/6443431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":95,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,10,10]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0470","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,10,10]]}}}